Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL436565 | 0.89 | LMNA (0.56) | MAPK1HTTSMN1; SMN2NPC1LMNA | |
| SCHEMBL7195606 | 0.85 | LMNA (0.54) | MAPK1HTTSMN1; SMN2HPGDNPC1 | |
| SCHEMBL4609604 | 0.84 | POLB (0.57) | MAPK1SRD5A2HTTSMN1; SMN2HPGD | |
| SCHEMBL12490393 | 0.84 | HTT (0.70) | MAPK1SRD5A2HTTSMN1; SMN2HPGD | |
| SCHEMBL11278601 | 0.83 | HTT (0.69) | MAPK1SRD5A2HTTSMN1; SMN2HPGD | |
| SCHEMBL17025499 | 0.82 | MAPK1 (0.50) | MAPK1SRD5A2HTTSMN1; SMN2HPGD | |
| SCHEMBL13783385 | 0.81 | MAPT (0.66) | MAPK1HTTSMN1; SMN2NPC1LMNA | |
| SCHEMBL11114087 | 0.80 | SRD5A2 (0.52) | MAPK1SRD5A2HTTSMN1; SMN2HPGD | |
| SCHEMBL15851085 | 0.80 | HSD17B1 (0.58) | MAPK1SRD5A2HTTSMN1; SMN2HPGD | |
| SCHEMBL30409629 | 0.79 | HDAC1 (0.58) | MAPK1SMN1; SMN2NPC1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115084-B2 | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2015-08-25 | — | — | US | disclosed |
| US-20130237528-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-12 | — | — | US | disclosed |
| US-20050250822-A1 | Substituted benzanilide compound and noxious organism controlling agent | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-11-10 | — | — | US | disclosed |
| EP-1538138-A1 | SUBSTITUTED BENZANILIDE COMPOUND AND PEST CONTROL AGENT | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 2005-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237528-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | PARP1, PARP2, PARP6 | MAPK1 2525/4885SRD5A2 2885/4885HTT 2019/4885 |
| US-20050250822-A1 | Substituted benzanilide compound and noxious organism controlling agent | GCN1, L3MBTL3, L3MBTL4 | MAPK1 652/4885SRD5A2 4243/4885HTT 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.